organization · Reporting owner
Atlas Venture Associates Opportunity II, LLC
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | 10% owner | March 01, 2024 | March 05, 2024 |
| Korro Bio, Inc.KRRO · Entity 6388 | 10% owner | April 22, 2024 | April 23, 2024 |
| Q32 Bio Inc.QTTB · Entity 5594 | 10% owner | March 25, 2024 | March 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date March 01, 2024 · Filed March 05, 2024
Jointly reported with Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,458,691 |
Reported balance
After 2024-03-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-03-01 · Sale · Disposed 29,435 · Balance 1,458,691 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 847,388 |
Reported balance
After 2024-03-01 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-03-01 · Sale · Disposed 17,099 · Balance 847,388 F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any.
F4: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.
F5: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.
Korro Bio, Inc.
Report date April 22, 2024 · Filed April 23, 2024
Jointly reported with Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 195,074 |
Reported balance
After 2024-04-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-04-22 · Purchase · Acquired 17,857 · Balance 195,074 F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.
Q32 Bio Inc.
Report date March 25, 2024 · Filed March 27, 2024
Jointly reported with Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 864,261 |
Reported balance
Holding disclosure · report date 2024-03-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 864,261 F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Opportunity Fund I, L.P. | 503,296 |
Reported balance
Holding disclosure · report date 2024-03-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 503,296 F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Opportunity Fund II, L.P. | 724,549 |
Reported balance
Holding disclosure · report date 2024-03-25 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 724,549 F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
F2: Shares held by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
F3: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Disc Medicine, Inc.
Report date January 23, 2024 · Filed January 25, 2024
Jointly reported with Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP
Section 16 reporting ended · disclosed 2024-01-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,402,186 |
Reported balance
After 2024-01-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-01-23 · Sale · Disposed 47,500 · Balance 1,402,186 F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 703,660 |
Reported balance
After 2024-01-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-01-23 · Sale · Disposed 82,500 · Balance 703,660 F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 198,326 |
Reported balance
After 2024-01-23 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-01-23 · Sale · Disposed 20,000 · Balance 198,326 F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any.
F2: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any.
F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any.
Sionna Therapeutics, Inc.
Report date February 10, 2025 · Filed February 10, 2025
Jointly reported with Atlas Venture Fund XI, L.P., Atlas Venture Associates XI, L.P., Atlas Venture Associates XI, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, LP
Section 16 reporting ended · disclosed 2025-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,886,293 |
Reported balance
After 2025-02-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-10 · Conversion · Acquired 2,886,293 · Balance 2,886,293 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Atlas Venture Opportunity Fund II, L.P. | 807,727 |
Last balance in matching sequence
After 2025-02-10 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2025-02-10 · Conversion · Acquired 747,727 · Balance 747,727 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Row 3 · 2025-02-10 · Purchase · Acquired 60,000 · Balance 807,727 F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
| Series Seed convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-10 · Conversion · Disposed 1,051,051 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-10 · Conversion · Disposed 1,806,317 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-10 · Conversion · Disposed 1,298,332 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-02-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-10 · Conversion · Disposed 61,463 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Atlas Venture Opportunity Fund II, L.P. | 0 |
Reported balance
After 2025-02-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-10 · Conversion · Disposed 1,092,504 · Balance 0 F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date.
F2: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any.
F3: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries C convertible preferred stock · Derivative | 1,092,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 8 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 747,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries C convertible preferred stock · Derivative | 61,463 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 7 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,068 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries B convertible preferred stock · Derivative | 1,298,332 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 6 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 888,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries A convertible preferred stock · Derivative | 1,806,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 5 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,236,271 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionSeries Seed convertible preferred stock · Derivative | 1,051,051 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · derivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 719,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | PurchaseCommon Stock | 60,000 | $18.00 | $1,080,000.00 |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P. Disclosed balance after: 807,727 F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionCommon Stock | 747,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Atlas Venture Opportunity Fund II, L.P. Disclosed balance after: 747,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). The general partner of AVOF II is Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP"). Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | ConversionCommon Stock | 2,886,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-017030 · ownership.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,886,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed convertible preferred stock, Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date. F2 · ownership.direct: These shares are held directly by Atlas Venture Fund XI, L.P. ("AVF XI"). The general partner of AVF XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by AVF XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| April 22, 2024 Filed Apr 23, 2024 17:23 UTC | Korro Bio, Inc. KRRO · Entity 6388 | PurchaseCommon Stock | 17,857 | $56.00 | $999,992.00 |
DisclosureSEC source: 0001415889-24-011385 · form4-04232024_090431.xml · nonDerivative · entry 1 Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,074 F1 · ownership.direct: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 17,099 | $30.05 | $513,824.95 |
DisclosureSEC source: 0001415889-24-006764 · form4-03052024_100352.xml · nonDerivative · entry 2 Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 847,388 F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 17:07 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 29,435 | $30.05 | $884,521.75 |
DisclosureSEC source: 0001415889-24-006764 · form4-03052024_100352.xml · nonDerivative · entry 1 Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,458,691 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.direct: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 210 | $25.25 | $5,302.50 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 18 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 864,487 F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive. F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 13,109 | $24.83 | $325,496.47 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 17 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 864,697 F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive. F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 360 | $25.25 | $9,090.00 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 16 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,488,126 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 22,567 | $24.83 | $560,338.61 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 15 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,488,486 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,430 | $25.25 | $61,357.50 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 14 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,698,091 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $25.255 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 152,244 | $24.83 | $3,780,218.52 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 13 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,700,521 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.25 to $25.235 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,216 | $24.68 | $54,690.88 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 12 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 877,806 F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive. F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 23,505 | $24.38 | $573,051.90 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 11 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 880,022 F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive. F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 3,821 | $24.68 | $94,302.28 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 10 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,511,053 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 40,455 | $24.38 | $986,292.90 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 9 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,514,874 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 25,779 | $24.68 | $636,225.72 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 8 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,852,765 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.62 to $24.76 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 272,923 | $24.38 | $6,653,862.74 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 7 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,878,544 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.62 to $24.615 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,580 | $23.98 | $133,808.40 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 6 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 903,527 F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive. F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 11,736 | $23.59 | $276,852.24 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 5 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 909,107 F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12). F8 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 9,603 | $23.98 | $230,279.94 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,555,329 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 20,205 | $23.59 | $476,635.95 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,564,932 F5 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12). F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 64,783 | $23.98 | $1,553,496.34 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,151,467 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.83 to $24.04 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 19:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 136,312 | $23.59 | $3,215,600.08 |
DisclosureSEC source: 0001415889-24-005777 · form4-02292024_120212.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,216,250 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.82 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (9), (10), (11) and (12). F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 23, 2024 Filed Feb 23, 2024 18:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 13,738 | $22.70 | $311,852.60 |
DisclosureSEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 6 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 920,843 F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive. F10 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 23, 2024 Filed Feb 23, 2024 18:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 23,648 | $22.70 | $536,809.60 |
DisclosureSEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 5 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,585,137 F7 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive. F8 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 23, 2024 Filed Feb 23, 2024 18:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 159,542 | $22.70 | $3,621,603.40 |
DisclosureSEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,352,562 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.205 to $22.92 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 18:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 119,360 | $22.66 | $2,704,697.60 |
DisclosureSEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,512,104 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $23.1566 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 18:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 35,164 | $23.14 | $813,694.96 |
DisclosureSEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,631,464 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7625 to $23.3899 inclusive. F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 18:58 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 149,337 | $22.44 | $3,351,122.28 |
DisclosureSEC source: 0001415889-24-005124 · form4-02232024_110219.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,666,628 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund XI, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.72 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6). F3 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:31 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 20,000 | $67.65 | $1,353,000.00 |
DisclosureSEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 198,326 F3 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund II, L.P. ("Atlas Opportunity II"). Atlas Venture Associates Opportunity II, L.P. ("Associates II") is the general partner of Atlas Opportunity II. Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. Each of Associates II and Associates II LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:31 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 82,500 | $67.65 | $5,581,125.00 |
DisclosureSEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 703,660 F2 · ownership.nature: These shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Opportunity I"). Atlas Venture Associates Opportunity I, L.P. ("Associates I") is the general partner of Atlas Opportunity I. Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. Each of Associates I and Associates I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Opportunity I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 16:31 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 47,500 | $67.65 | $3,213,375.00 |
DisclosureSEC source: 0001209191-24-002231 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,402,186 F1 · ownership.direct: These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas X"). Atlas Venture Associates X, L.P. ("Associates X") is the general partner of Atlas X. Atlas Venture Associates X, LLC ("Associates X LLC") is the general partner of Associates X. Each of Associates X and Associates X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 16:55 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 934,581 | $10.70 | $10,000,016.70 |
DisclosureSEC source: 0001209191-22-061243 · doc4.xml · nonDerivative · entry 1 Atlas Venture Opportunity Fund II, L.P. · CIK 0001885327 · 10% owner Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Atlas Venture Associates Opportunity II, LP · CIK 0001935814 · 10% owner Atlas Venture Associates Opportunity II, LLC · CIK 0001935810 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 934,581 F1 · ownership.direct: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, L.P. ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. Each of AVAO II LP and AVAO II LLC disclaims Section 16 beneficial ownership of the securities held by AVOF II, except to the extent of its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.